2644 related articles for article (PubMed ID: 18490011)
41. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
[TBL] [Abstract][Full Text] [Related]
42. Effects of alpha-tocopherol on an animal model of tauopathies.
Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
[TBL] [Abstract][Full Text] [Related]
43. Divergent phosphorylation pattern of tau in P301L tau transgenic mice.
Deters N; Ittner LM; Götz J
Eur J Neurosci; 2008 Jul; 28(1):137-47. PubMed ID: 18662339
[TBL] [Abstract][Full Text] [Related]
44. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
45. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
46. Modulation of tau pathology in tau transgenic models.
Brion JP; Ando K; Heraud C; Leroy K
Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
[TBL] [Abstract][Full Text] [Related]
47. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
48. [Animal models of tauopathies].
Higuchi M
Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
[TBL] [Abstract][Full Text] [Related]
49. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
50. Mouse models of impaired fear memory exhibit deficits in amygdalar LTP.
Schimanski LA; Nguyen PV
Hippocampus; 2005; 15(4):502-17. PubMed ID: 15744733
[TBL] [Abstract][Full Text] [Related]
51. Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model.
Dassie E; Andrews MR; Bensadoun JC; Cacquevel M; Schneider BL; Aebischer P; Wouters FS; Richardson JC; Hussain I; Howlett DR; Spillantini MG; Fawcett JW
Neurobiol Aging; 2013 May; 34(5):1355-68. PubMed ID: 23273572
[TBL] [Abstract][Full Text] [Related]
52. Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature.
Przybyla M; van Eersel J; van Hummel A; van der Hoven J; Sabale M; Harasta A; Müller J; Gajwani M; Prikas E; Mueller T; Stevens CH; Power J; Housley GD; Karl T; Kassiou M; Ke YD; Ittner A; Ittner LM
Brain; 2020 Jun; 143(6):1889-1904. PubMed ID: 32375177
[TBL] [Abstract][Full Text] [Related]
53. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice.
Pennanen L; Welzl H; D'Adamo P; Nitsch RM; Götz J
Neurobiol Dis; 2004 Apr; 15(3):500-9. PubMed ID: 15056457
[TBL] [Abstract][Full Text] [Related]
54. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
55. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
56. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.
Van der Jeugd A; Hochgräfe K; Ahmed T; Decker JM; Sydow A; Hofmann A; Wu D; Messing L; Balschun D; D'Hooge R; Mandelkow EM
Acta Neuropathol; 2012 Jun; 123(6):787-805. PubMed ID: 22532069
[TBL] [Abstract][Full Text] [Related]
57. Selective degeneration of septal and hippocampal GABAergic neurons in a mouse model of amyloidosis and tauopathy.
Loreth D; Ozmen L; Revel FG; Knoflach F; Wetzel P; Frotscher M; Metzger F; Kretz O
Neurobiol Dis; 2012 Jul; 47(1):1-12. PubMed ID: 22426397
[TBL] [Abstract][Full Text] [Related]
58. Transgenic zebrafish model of neurodegeneration.
Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of memory loss in Abeta and tau mouse models.
Ashe KH
Biochem Soc Trans; 2005 Aug; 33(Pt 4):591-4. PubMed ID: 16042551
[TBL] [Abstract][Full Text] [Related]
60. The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
Rademakers R; Cruts M; van Broeckhoven C
Hum Mutat; 2004 Oct; 24(4):277-95. PubMed ID: 15365985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
